A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for stopping the disease completely and significantly lowering treatment cost. CML is a cancer of the white blood cells and accounts for 20% of adult leukemia.The study’s researchers combined two drugs that inhibit the BCR-ABL gene, which is found in most patients with CML.
The gene is a “hybrid” that forms when...
The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which concerns many top oncologists. In...